← Back

Wire · opportunities

Vittoria's Senza5 CART5 hits 88% ORR in Phase I relapsed T-cell lymphoma

Published

18 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at allsci.com →

◆ Verified

Fusion42 · 19 November 2026 · Fusion42 review

Vittoria Biotherapeutics announced that its Phase I VIPER-101 trial of Senza5 CART5, a CD5-targeting autologous CAR-T therapy for relapsed or refractory T-cell lymphoma, achieved an 88% overall response rate and 75% complete response rate. The US FDA granted Senza5 CART5 RMAT designation in November 2026, facilitating expedited regulatory engagement for pivotal trials.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You face faster development paths with FDA tools like RMAT, but you must prepare trial designs quickly to keep pace with regulatory expectations around novelty therapies in oncology. Delay risks losing lead time over rivals.

◆ Coverage

1 source · 18 Nov 2026

◆ Related on Wire

◆ Topics

Biotechcar-tt-cell-lymphomarmtaorphan-drugclinical-trials